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ABSTRACT
A 49-year-old Japanese man with bronchial asthma
was admitted to hospital because of acute lobar pneu-
monia. A diagnosis of acute tuberculous pneumonia
was made based on the pathologic findings of lung
biopsy specimens and bacteriologic examination. For
the 5 years before the onset of pneumonia, the patient
had been treated with inhaled beclomethasone dipro-
pionate (600 m g/day) and was well controlled.
Laboratory findings revealed no immunosuppressive
conditions, nor had the patient used oral corticos-
teroids for the treatment of his asthma. A tuberculin
skin test had been negative approximately 30 years
ago and annual chest X-ray examination had shown
no evidence of tuberculosis over the past 5 years.
Fiberoptic broncoscopic examination showed no evi-
dence of bronchial tuberculosis or perforated lymph
nodes. Because acute tuberculous lobar pneumonia
in the lower lung field is rare, except in patients receiv-
ing oral corticosteroids or with immunodeficiency
conditions, in this patient the inhalation of corticos-
teroids may have predisposed him to the onset of this
condition.
Key words: asthma, beclomethasone dipropionate,
inhalation therapy, lower lung field tuberculosis, oral
corticosteroid, tuberculous pneumonia.
INTRODUCTION
Inhalation of corticosteroids has been used as first-line
treatment of bronchial asthma worldwide for the past
20 years.1 This treatment modality has not been thought to
predispose patients to infectious diseases of the airway
and lungs, with the exception of the development oropha-
ryngeal candidiasis as a local side effect.2–4 In the present
study, we report on a case of acute tuberculous pneumo-
nia (ATBP) confined to the lower lung field in a patient with
asthma that was treated with inhaled beclomethasone
dipropionate (BDP).
CASE REPORT
A 49-year-old Japanese man with asthma was admitted to
hospital with fever (37.8°C), productive cough and
general fatigue for 2 days. On admission, the patient’s
weight was 66 kg, his height was 169 cm and his state of
nutrition was good. No abnormal physical signs
were observed, except coarse rales on the left anterior
chest wall. Chest X-ray films showed consolidation in the
lingular segment without hilar lymph node enlargement
(Fig. 1). The chest X-ray film obtained the previous
year was normal. Asthmatic symptoms had been well 
controlled in the patient using inhaled BDP (600 m g/day)
for the past 5 years and daily peak expiratory flow values
had been within the normal range. Abnormal laboratory
findings on admission were an increased erythrocyte
sedimentation rate, C-reactive protein and neutrophilia
(Table 1). No immunologic abnormalities were found and
human immunodeficiency virus (HIV) titers were negative.
Results of bacteriologic examination of the sputum for 
3 consecutive days were unremarkable. Based on these
findings, the patient was tentatively treated with minocy-
cline, clindamycine and cefoperazone–sulbactam, in that
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order, over a 14 day period. However, his infectious
symptoms deteriorated and consolidation on chest X-ray
film expanded into the left lower lobe. A high-resolution
computed tomographic scan showed a high-density
area occupying the entire lingular segment with air 
bronchograms and acinar high-density patterns in the
lower lung field (Fig. 2). Because the tuberculin skin test
was strongly positive on the 10th day of admission, 
even though the patient had had a Bacillus Calmette–
Guérin vaccination in childhood and had never been in
contact with any person who had been diagnosed with
tuberculosis, fiberoptic bronchoscopic examination was
performed to confirm the pathogenesis. There were
no remarkable abnormalities in the bronchial epithelial
surface nor perforated lymph nodes into the lumen.
Histologic examination using the specimens obtained
by transbronchial lung biopsy showed multiple immature
epithelioid granulomas without central necrosis (Fig. 3).
Based on these histologic findings, a diagnosis of tuber-
culous pneumonia was made. Treatment with common
antibiotics was discontinued and the patient was then
treated using a combination of the following drugs: isoni-
azid (0.3 g/day), rifampicin (0.45 g/day) and ethambutol
(0.75 g/day). Culture of the specimen obtained from
bronchial lavage showed 11 colonies of Mycobacterium
tuberculosis at the 4th week and culture of sputum also
showed 15 colonies of M. tuberculosis at the 6th week.
Both were not drug-resistant in vitro. Symptoms and
abnormal shadows on chest X-ray film completely
resolved in 2 months (Fig. 4).
DISCUSSION
Unlike typical pulmonary tuberculosis, ATBP resembles
acute bacterial pneumonia and is diagnosed on the basis
of the clinical course and chest X-ray findings.5,6 It is
thought that ATBP is initiated by hypersensitivity to massive
inhalation of tubercle bacillus protein7,8 originating from
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Fig. 1 Chest X-ray films on admission show hazy opacities in
the lingular segment of the left lung.
Table 1 Laboratory findings on admission
Hematology
Red blood cells (/mm3) 541 · 104
Hemoglobin (g/dL) 15.8
Hematocrit (%) 47.8
Platelets (/mm3) 35.6 · 104
White blood cells (/mm3) 9800
Neutrophils (%) 73
Eosinophils (%) 5
Monocytes (%) 8
Basophils (%) 1
Lymphocytes (%) 12
Biochemistry
Total protein (g/dL) 7.1
Albumin (g/dL) 4.1
Total bilirubin (mg/dL) 0.4
Glutamic oxaloacetic transaminase 
(mU/mL) 13
Glutamic pyruvic transaminase (mU/mL) 11
Lactate dehydrogenase (mU/mL) 182
Blood urea nitrogen (mg/dL) 9
Creatinine (mg/dL) 0.8
Na (mEq/L) 141
K (mEq/L) 4.2
Cl (mEq/L) 101
Serology and immunology
Erythrocyte sedimentation rate (mm/h) 41
C-Reactive protein (mg/dL) 7.2
IgG (mg/dL) 1177
IgM (mg/dL) 257
IgA (mg/dL) 333
Lymphocytes
T cell (%) 66.8
B cell (%) 10.6
T cell subsets
CD4+ 44.7
CD8+ 22.1
Anti-Mycoplasma pneumoniae antibodies 
(IHA) < 40
Anti-HIV (ELISA) Negative
Blood gas analysis (room air)
pH 7.420
PaO2 (mmHg) 79.5
PaCO2 (mmHg) 32.8
Sputum
Bacteriology Negative
Cytology Class I
Tuberculin skin test* 37 mm redness
and 13 mm
induration
*Performed on the 10th day of admission. IHA, indirect hemagglu-
tination.
tubercle bacillus inhaled into peripheral lung tissue
through perforated bronchial epithelium from infected
lymph nodes or by primary infection.9 Because the lung
lesion is caused by a hypersensitivity reaction to the tuber-
cle bacillus protein, the bacilli are not necessarily
detected in specimens.8,10 The present case of ATBP was
classified as ‘lower lung field tuberculosis’ on the basis of
findings of chest X-ray films,11 in which the development
of the lesion is mostly caused by the perforation of
infected hilar lymph nodes and spread of bacilli to the
lung parenchyma.11,12 However, because the present
case did not show any evidence of perforated lymph
nodes by fiberoptic bronchoscopic examination and the
previous tuberculin skin test was negative, the ‘lower lung
field tuberculosis’ could have been due to primary infec-
tion rather than reactivation or secondary infection.
Previous studies11,13–15 have shown that ‘lower lung field
tuberculosis’ occurs only in 1–7% of patients with pul-
monary tuberculosis and that it is rarely caused by
primary infection. Therefore, patients tend to be misdiag-
nosed initially and treatment is delayed.8,15 In fact, we
had administered common antibiotics to this patient
under the tentative diagnosis of mycoplasma or other
bacterial pneumonia before ATBP was confirmed.
Inhaled corticosteroids for the treatment of asthma
have been used throughout the world since 19721 and
are recognized as very effective in controlling asthma
symptoms.16 Although these agents have not been shown
to increase the risk of lung infection,2–4 there are two
reports that have shown a relationship between the
incidence of pulmonary tuberculosis and inhaled corti-
costeroids in patients with asthma. Horton and Spector
reported a case of pulmonary tuberculosis in a 43-year-
old patient with asthma who had been treated using
inhaled BDP at 800 m g/day and oral corticosteroids.17
In another report, Shaikh described eight cases of 
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Fig. 2 High-resolution computed tomography of the chest
shows a high-density area in the entire lingular segment and
lower lobe with air bronchograms.
Fig. 3 Histologic features of the specimen obtained by trans-
bronchial lung biopsy show multiple immature epithelioid
granulomas without central necrosis. (Hematoxylin–eosin stain;
original magnification · 40.)
Fig. 4 A chest X-ray film 2 months after antitubercular treat-
ment shows complete improvement.
pulmonary tuberculosis of 548 patients with asthma who
were using inhaled BDP (400–800 m g/day).18 All eight
cases had typical pulmonary tuberculosis associated
with a cavity in the apical–posterior segment. Although
there is no evidence to suggest that inhaled cortico-
steroids, even in high doses, increase the risk of
pulmonary tuberculosis,19 the incidence (1.48%) of
pulmonary tuberculosis in patients who used inhaled
corticosteroids, as reported by Shaikh,18 was much
higher than that in the general population, which, for
example, is approximately 0.035% in Japan.20 It is
widely known that systemic corticosteroid therapy can
reactivate latent tuberculosis or increase the risk of
primary tuberculosis.21–25 Immunocompromised individ-
uals, such as those that are HIV positive, also have a
high incidence of pulmonary tuberculosis, including
‘lower lung field tuberculosis’.26,27 The present patient
was HIV negative and had no evidence of immunologic
abnormalities. Therefore, it is possible that inhaled corti-
costeroids could have predisposed this patient to the
development of tuberculosis because they have higher
topical activity than oral corticosteroids and decrease 
T lymphocyte activity in the epithelium.
More than 200 patients have been diagnosed with
active tuberculosis in the past 10 years in our institute
and more than 2000 patients with asthma have been
treated with inhaled BDP during the same period.
However, the current case of tuberculosis was the first at
our institute of a patient who had been treated with
inhaled corticosteroids for asthma. Therefore, inhaled
corticosteroids do not appear to increase the risk of
tuberculosis and the circumstances of development of
tuberculosis in our patient may be coincidental.
However, Sahn and Lakshminarayan reported on six
patients with ‘lower lung field tuberculosis’ on chest 
X-ray films of a total of 13 patients in whom tuberculosis
had developed after oral corticosteroid treatment28 and
this type of tuberculosis is uncommon in patients not
using corticosteroids. Because the present case had
primary ‘lower lung field tuberculosis’, which is very
rare, the effect of inhaled corticosteroids cannot be
ruled out. Moreover, because inhaled corticosteroids
have a dose-dependent systemic effect, although less
than oral corticosteroid treatment,29 careful follow up
should be undertaken for patients with asthma who are
treated with inhaled corticosteroids. When acute pneu-
monia develops in these patients, atypical pulmonary
tuberculosis should be taken into account as a differen-
tial diagnosis.
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